Feasibility and acute toxicities of radioimmunoguided prostate brachytherapy

Rodney J. Ellis, D. Bruce Sodee, John P. Spirnak, Kurt H. Dinchman, Andrew W. O'Leary, Michael A. Samuels, Martin I. Resnick, Timothy J. Kinsella

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


Purpose: We present a technique that fuses pelvic CT scans and ProstaScint images to localize areas of disease within the prostate gland to customize prostate implants. Additionally, the acute toxicity results from the first 43 patients treated with this technique are reviewed. Methods and Materials: Between 2/97 and 8/98, 43 patients with clinical stage II prostate adenocarcinoma received ultrasound-guided transperineal implantation of I-125 or Pd-103 seeds. The median patient age was 70 years (range 49-79). Prior to treatment, the median Gleason score and prostate-specific antigen (PSA) were 6 (range 3-8) and 7.5 (range 1.8-16.6 ng/mL), respectively. The median follow-up was 10 months (range 2.9-20.4 months). Results: The median PSA value at 10 months is 0.7 ng/mL. Significant acute complications within the first month following implantation included 13 Grade I urinary symptoms, 24 Grade II urinary symptoms, 6 Grade III symptoms, and no Grade IV complications. Beyond 4 months, complications included 12 Grade I urinary symptoms, 17 Grade II urinary symptoms, 1 Grade III, and 1 Grade IV complications. Conclusions: The image fusion of the pelvic CT scan and ProstaScint scans helped identify regions within the prostate at high risk of local failure, which were targeted with additional seeds during implantation. (C) 2000 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)683-687
Number of pages5
JournalInternational Journal of Radiation Oncology Biology Physics
Issue number3
StatePublished - Oct 1 2000

All Science Journal Classification (ASJC) codes

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research


Dive into the research topics of 'Feasibility and acute toxicities of radioimmunoguided prostate brachytherapy'. Together they form a unique fingerprint.

Cite this